Neuprozyme Therapeutics ApS — Credit Rating and Financial Key Figures

CVR number: 40010106
Agern Alle 3, 2970 Hørsholm
Free credit report Annual report

Income statement (kDKK)

2020
2021
2022
2023
2024
Fiscal period length1212121212
Net sales
Gross profit1 031.28576.18-1.07-26.50-27.48
EBIT1 031.00576.00-1.00-26.50-27.48
Other financial income1.761.0124.760.491.28
Other financial expenses-2.16-18.09-50.88
Reduction non-current investment assets-1 100.99
Pre-tax profit-70.06559.00-26.98-26.02-26.21
Income taxes- 218.94- 123.005.981.150.63
Net earnings- 289.00436.00-21.00-24.87-25.57

Assets (kDKK)

2020
2021
2022
2023
2024
Intangible assets total
Tangible assets total
Investments total0.37-0.42-0.30
Long term receivables total
Inventories total
Current trade debtors1 566.60
Current amounts owed by group member comp.36.605.987.588.71
Current other receivables5.1779.192.130.24
Short term receivables total41.781 645.798.117.588.95
Cash and bank deposits6.8549.63150.20125.86100.13
Cash and cash equivalents6.8549.63150.20125.86100.13
Balance sheet total (assets)49.001 695.00158.00133.43109.09

Equity and liabilities (kDKK)

2020
2021
2022
2023
2024
Share capital50.0050.0050.0050.0050.00
Other reserves0.08-0.020.20
Retained earnings-43.08- 331.98103.8082.8157.93
Profit of the financial year- 289.00436.00-21.00-24.87-25.57
Shareholders equity total- 282.00154.00133.00107.9382.36
Provisions-0.080.02-0.20
Non-current liabilities total
Current trade creditors668.70
Current owed to group member288.21847.711.23
Other non-interest bearing current liabilities42.5025.0025.5025.5025.50
Current liabilities total330.711 541.4025.5025.5026.73
Balance sheet total (liabilities)48.631 695.42158.31133.43109.09
CreditReports API
  • Company information
  • Financial data
  • Credit risk data
  • All 400,000+ Danish companies

Try the full version of our system for free
Bankruptcy risk visualization example

... and more!

No registration needed.